LTT Biopharma's IIP Agent PC-SOD Shows Promise In Phase II Trials
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based LTT Biopharma announced June 9 that its idiopathic interstitial pneumonia treatment, superoxide dismutase drug PC-SOD showed promise of becoming a therapeutic drug during Phase II trials. The company has decided to search for other pharmaceutical companies to jointly develop the drug and start Phase III trials. (Click here for more - Japanese language ) "LTT Shares Jump To Stop Price On PC-SOD's Possibility Of Being A Therapeutic Drug" - Reuters Japan (6/9/08)